We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Rheumatology

Journal Scan / Research · November 03, 2022

Recapture and Retreatment Rates With Ixekizumab After Withdrawal of Therapy in Patients With Axial Spondyloarthritis

Annals of the Rheumatic Diseases


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of the Rheumatic Diseases
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
Ann. Rheum. Dis 2022 Sep 13;[EPub Ahead of Print], RBM Landewé, D Poddubnyy, P Rahman, FE Van den Bosch, R Bolce, S Liu Leage, JR Lisse, SY Park, L Gensler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading